Skip to main content
. 2022 Jan 5;71(8):1897–1908. doi: 10.1007/s00262-021-03102-3

Fig. 2.

Fig. 2

Tumor response in each disease cohort in phase 1b. Each bar represents one patient. ≥ 2L, second-line or after; 1L, first-line; CC/GBC, cholangiocarcinoma or gallbladder carcinoma; HCC, hepatocellular carcinoma; MSI-H/dMMR, solid tumors with MSI-H/dMMR phenotype; GAC/GEJAC, gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer. PR, partial response; SD, stable disease; PD, progressive disease